-
公开(公告)号：KR1020080034575A
公开(公告)日：2008-04-22
申请号：KR1020060100703
申请日：2006-10-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/047 , A61K31/13
CPC classification number: A61K31/047
Abstract: A method for inhibiting the expression of CCL27/CTACK(Cutaneous T-cell-attracting chemokine) is provided to regulate SPC(sphingosylphosphorylcholine) inducing expression of CCL27/CTACK, so that the method is useful for prevention and treatment of diseases associated with overexpression of CCL27/CTACK including atopic dermatitis, psoriasis and inflammatory skin disease. The expression of CCL27/CTACK is inhibited by administering an effective amount of sphingosylphosphorylcholine regulator capable of inhibiting activity of SPC or competing with the mechanism of SPC inducing overexpression of CCL27/CTACK to a mammal requiring the expression reduction of CCL27/CTACK. A method for screening the SPC regulator comprises the steps of: (1) treating a testing cell such as keratinocyte with 2-10 muM of SPC or its derivatives to induce overexpression of CCL27/CTACK; and (2) treating the overexpression of CCL27/CTACK-induced cell with a candidate material and measuring the expression inhibition of CCL27/CTACK. Further, the mammal has an atopic dermatitis or psoriasis.
Abstract translation: 提供抑制CCL27 / CTACK（皮肤T细胞吸引趋化因子）表达的方法，以调节诱导CCL27 / CTACK表达的SPC（鞘氨醇磷酰胆碱），从而该方法可用于预防和治疗与过表达相关的疾病 CCL27 / CTACK包括特应性皮炎，牛皮癣和炎性皮肤病。 通过施用有效量的能够抑制SPC活性或与诱导CCL27 / CTACK过表达的SPC的机制竞争需要CCL27 / CTACK表达降低的哺乳动物，CCL27 / CTACK的表达被抑制。 用于筛选SPC调节剂的方法包括以下步骤：（1）用2-10μM的SPC或其衍生物处理测试细胞如角质细胞，以诱导CCL27 / CTACK的过度表达; 和（2）用候选物质治疗CCL27 / CTACK诱导的细胞的过度表达，并测量CCL27 / CTACK的表达抑制。 此外，哺乳动物具有特应性皮炎或牛皮癣。
-
公开(公告)号：KR1020070107961A
公开(公告)日：2007-11-08
申请号：KR1020060040588
申请日：2006-05-04
Applicant: (주)아모레퍼시픽
IPC: A61K36/9068 , A61K36/754
CPC classification number: A61K36/00 , A61K8/97 , A61K9/00 , A61K36/754 , A61K36/9062 , A61K36/9068 , A61K2236/33 , A61Q19/00 , A61Q19/005 , Y10S514/857
Abstract: A composition comprising extracts of crude drugs is provided to suppress and relieve itching caused by inflammatory and atopic dermatitis without side effects such as toxicity and skin irritation. A composition for suppressing and relieving itching comprises 0.1-10 wt.% of the extracts of Zingiber officinale Rosc., Evodia officinalis and Alpinia katsumadai Hayata which are prepared by extracting them with water, C1-C4 lower alcohol or a mixed solvent thereof. The daily dosage of crude drug extracts is 0.001-100 mg/kg, preferably 0.1-30 mg/kg and the composition is a pharmaceutical composition having a formulation selected from ointment, plaster, lotion and liniment, or a cosmetic composition having a formulation selected from skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
Abstract translation: 提供包含生药提取物的组合物以抑制和缓解由炎性和特应性皮炎引起的瘙痒，而没有副作用，例如毒性和皮肤刺激。 用于抑制和缓解瘙痒的组合物包括通过用水，C1-C4低级醇或其混合溶剂提取它们制备的姜黄提取物的0.1-10重量％的提取物。 生药提取物的日剂量为0.001-100mg / kg，优选0.1-30mg / kg，并且组合物是具有选自软膏，石膏，洗剂和搽剂的制剂的药物组合物或具有选择的制剂的化妆品组合物 从皮肤洗剂，皮肤柔肤剂，皮肤调色剂，收敛剂，乳液，乳液，滋润乳液，营养乳液，按摩霜，营养霜，保湿霜，护手霜，粉底，精华，营养精华，包装，肥皂，清洁泡沫，清洁 洗剂，清洁霜，身体乳液和身体清洁剂。
-
公开(公告)号：KR1020060052445A
公开(公告)日：2006-05-19
申请号：KR1020050104962
申请日：2005-11-03
Applicant: (주)아모레퍼시픽
IPC: A61K31/685 , A61K31/66
Abstract: 본 발명은 스핑고실포스포릴콜린(Sphingosylphosphorylcholine; SPC) 또는 그 유도체의 용도에 관한 것으로서, 보다 상세하게는 상기 스핑고실포스포릴콜린의 투여량을 조절하여 동물에 가려움을 유발하는 방법, 가려움증 억제 물질을 스크리닝하는 방법 및 스크리닝한 가려움증 억제 물질의 약효를 평가하는 방법에 관한 것이다. 본 발명에 의한 스핑고실포스포릴콜린 또는 그 유도체는 가려움증을 이해하고 연구하는데 유용하며, 이를 바탕으로 가려움증 치료 약을 검색하거나 약효를 평가하여 개발하는데 매우 유용하게 사용될 수 있다.
가려움증, 스핑고실포스포릴콜린, 가려움증 억제 물질-
公开(公告)号：KR1020060035140A
公开(公告)日：2006-04-26
申请号：KR1020040084495
申请日：2004-10-21
Applicant: (주)아모레퍼시픽
IPC: A61K36/28 , A61K36/9064 , A61K36/232 , A61P17/00
Abstract: 본 발명은 소자
(Perillae Semen), 우방자
(Arctii Semen) 및 초두구
(Alpiniae Katsumadaii Semen) 로 이루어진 군에서 선택된 1종 이상; 및 당귀
(Angelicae Gigantis Radix) 및 부평초
(Spirodelae Herba) 추출물로 이루어진 군에서 선택된 1종 이상의 식물 추출물을 함유하는 피부 외용제 조성물로서, IgE 매개성 알러지 반응 억제 능력에 의해 아토피성 피부염, 접촉성 피부염, 건선 등의 피부질환을 치료 또는 예방하기 위해 사용될 수 있다.
소자, 우방자, 초두구, 당귀, 부평초, 면역반응 억제, 아토피성 피부염, 접촉성 피부염, 건선-
25.发明授权
公开(公告)号：KR101871922B1
公开(公告)日：2018-07-02
申请号：KR1020110122622
申请日：2011-11-23
Applicant: (주)아모레퍼시픽
Abstract: 본발명은케모카인을함유하여피부또는모발에서의성체멜라닌세포이동을촉진시키는조성물에관한것으로, 보다상세하게는케모카인유전자를함유하여저색소성질환치료에사용하는성체멜라닌세포이동을촉진시키는조성물에관한것으로상기저색소성질환에는백반증또는백모인것을특징으로한다. 또한본 발명은피부활성물질탐색용키트및 이를이용하여피부활성물질을탐색하는방법에관한것으로, 보다상세하게는케모카인(chemokine) 유전자를포함하는탐색키트를이용하여피부세포에서케모카인유전자발현을유도하는후보물질을분리, 정제함으로써미백물질및 저색소성질환치료용물질등의피부활성물질을탐색해내는피부활성물질탐색용키트및 이를이용하여피부활성물질을탐색하는방법에관한것이다.
-
Patent Agency Ranking
公开(公告)号：KR101859500B1
公开(公告)日：2018-05-21
申请号：KR1020100121220
申请日：2010-12-01
Applicant: (주)아모레퍼시픽
Abstract: 본발명은콜라겐 4, 라미닌, 니도젠및 프로테오글라이칸을포함하는 3차원매트릭스용조성물및 상기조성물을이용하여제조한 3차원매트릭스를개시한다. 또한본 발명은상기 3차원매트릭스를이용하여세포를배양하는방법을개시한다.
-
公开(公告)号：KR101210008B1
公开(公告)日：2012-12-07
申请号：KR1020050104962
申请日：2005-11-03
Applicant: (주)아모레퍼시픽
IPC: A61K31/685 , A61K31/66
Abstract: 본발명은스핑고실포스포릴콜린(Sphingosylphosphorylcholine; SPC) 또는그 유도체의용도에관한것으로서, 보다상세하게는상기스핑고실포스포릴콜린의투여량을조절하여동물에가려움을유발하는방법, 가려움증억제물질을스크리닝하는방법및 스크리닝한가려움증억제물질의약효를평가하는방법에관한것이다. 본발명에의한스핑고실포스포릴콜린또는그 유도체는가려움증을이해하고연구하는데유용하며, 이를바탕으로가려움증치료약을검색하거나약효를평가하여개발하는데매우유용하게사용될수 있다.
-
28.发明授权
公开(公告)号：KR101018819B1
公开(公告)日：2011-03-04
申请号：KR1020087019182
申请日：2007-02-14
Applicant: (주)아모레퍼시픽
IPC: A61K31/17 , A61K31/765 , A61P17/00
CPC classification number: A61K9/0014 , A61K31/17 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/32
Abstract: 본 발명은 바닐로이드 수용체 길항제로서 티오우레아 유도체와 약제학적으로 허용가능한 담체를 함유하는 외용제 조성물 및 이의 약제학적 용도에 관한 것이다.
본 발명의 외용제 조성물은 피부투과와 안정성에서 우수하며 소양성 또는 자극성 피부질환에 유용하다.-
公开(公告)号：KR1020100031704A
公开(公告)日：2010-03-24
申请号：KR1020100011766
申请日：2010-02-09
Applicant: (주)아모레퍼시픽
IPC: A61K36/906 , A61K36/254 , A61K36/74 , A61P17/00
CPC classification number: A61K8/97 , A61K36/906 , Y10S514/857
Abstract: PURPOSE: A skin external composition is provided to suppress abnormally activated T lymphocyte-mediated immune response and to treat or prevent atopic dermatitis, contact dermatitis and psoriasis. CONSTITUTION: A cosmetic composition for relieving T lymphocyte-mediated skin immune disorder contains 0.001-10 weight% of Dalbergiae odoriferae lignum extract as an active ingredient. A pharmaceutical composition for treating T lymphocyte-mediated skin immune disorder contains Dalbergiae odoriferae lignum extract as an active ingredient.
Abstract translation: 目的：提供皮肤外用组合物以抑制异常活化的T淋巴细胞介导的免疫应答，并治疗或预防特应性皮炎，接触性皮炎和牛皮癣。 构成：用于缓解T淋巴细胞介导的皮肤免疫病症的化妆品组合物含有0.001-10重量％的檀香属木um提取物作为活性成分。 用于治疗T淋巴细胞介导的皮肤免疫病症的药物组合物含有檀香木提取物作为活性成分。
-
公开(公告)号：KR1020100031118A
公开(公告)日：2010-03-19
申请号：KR1020100011767
申请日：2010-02-09
Applicant: (주)아모레퍼시픽
IPC: A61K36/8984 , A61P17/00
Abstract: PURPOSE: A skin external composition is provided to suppress abnormally activated T lymphocyte-mediated immune response and relieve atopic dermatitis, contact dermatitis, and psoriasis. CONSTITUTION: A cosmetic composition for relieving T lymphocyte-mediated dermal immune diseases contains Dendrobii herba extract as an active ingredient. The dermal immune diseases include atopic dermatitis, contact dermatitis, or psoriasis. A pharmaceutical composition for relieving T lymphocyte-mediated dermal immune disease contains the Dendrobii herba extract as an active ingredient.
Abstract translation: 目的：提供皮肤外用组合物，以抑制异常活化的T淋巴细胞介导的免疫反应并缓解特应性皮炎，接触性皮炎和牛皮癣。 构成：用于缓解T淋巴细胞介导的真皮免疫疾病的化妆品组合物含有Dendrobii草药提取物作为活性成分。 皮肤免疫疾病包括特应性皮炎，接触性皮炎或牛皮癣。 用于缓解T淋巴细胞介导的真皮免疫疾病的药物组合物含有Dendrobii草药提取物作为活性成分。
-
-
-
-
-
-
-
-
-
Search Results
55
records
(took 0.026 seconds)
